The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number
of medical conditions; however, the subject remains controversial and no official statements …

Patent foramen ovale (PFO) concerns nearly a quarter of the general population and
incidence may reach up to 50% in patients with cryptogenic stroke. Recent randomized …

Background: Residual shunt is observed in up to 25% of patients after patent foramen ovale
(PFO) closure, but its long-term influence on stroke recurrence currently is unknown …

Background Percutaneous closure of patent foramen ovale (PFO) is conventionally
performed under continuous transesophageal echocardiographic (TEE) guidance. We …

Aims Percutaneous closure of patent foramen ovale (PFO) in cryptogenic cerebrovascular
events is an alternative to medical therapy. The interpretation of residual shunts after …

Aims: To evaluate the relationship between the anatomic features of the fossa ovalis (FO)
and residual right-toleft shunt (RLS) after percutaneous patent foramen ovale (PFO) closure …

Background Pembrolizumab is an immune check-point inhibitor (ICI), which acts by blocking
the T lymphocyte PD-1 inhibitor receptor. It has been increasingly used in advanced or non …

Objectives Assess the evolution of right‐to‐left shunt (RLS) after transcatheter patent
foramen ovale (PFO) closure. Background Despite the high number of interventional …

Aims: Residual shunt following percutaneous patent foramen ovale (PFO) closure has been
described in up to 49% of patients and is associated with recurrent cerebrovascular events …

Background Recent published trials have shown the efficacy of transcatheter closure of
patent foramen ovale (PFO) for preventing recurrent cryptogenic cerebrovascular events …